Email this article 
Pharmacoeconomical efficiency of singulair in children of preschool age having atopic diseases
- Authors: Volkova NA1, Beltyukov EK2
-
Affiliations:
- Federal State Institution of Health Central Medical-Sanitary Department No. 91 of the FMBA of Russia
- Federal State Educational Institution Highest Vocational Education Ural State Medical University Ministry of Health of Russia
- Issue: Vol 12, No 3 (2015)
- Pages: 47-50
- Section: Articles
- Submitted: 10.03.2020
- Published: 15.12.2015
- URL: https://rusalljournal.ru/raj/article/view/451
- DOI: https://doi.org/10.36691/RJA451
- ID: 451
Cite item
Open Access
Access granted
Abstract
The aim of study. To estimate pharmacoeconomical efficiency of the antagonist of the leykotriene receptors singulair in children of preschool age having atopic diseases. Materials and methods. Open randomized comparative study of pharmacoeconomical efficiency of a singulair in parallel groups of the children of preschool age having atopic diseases was conducted. Results. Including of singulair in therapy of preschool age children with atopic diseases reduced the cost in general by 10,6%, lowered the cost per unite of efficiency by 1,5 times during treatment and by 2 times in a half of year after finishing of the singulair therapy. Conclusion. Including of singulair in basic therapy of preschool age children with atopic diseases increases clinical and economic efficiency.
Keywords
Full Text
About the authors
N A Volkova
Federal State Institution of Health Central Medical-Sanitary Department No. 91 of the FMBA of Russia
Email: Volkov-vaa@yandex.ru
E K Beltyukov
Federal State Educational Institution Highest Vocational Education Ural State Medical University Ministry of Health of Russia
References
- Bisgaard H., Zielen S., Garcia-Garcia M.L. et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Amer. J. Respir. Crit. Care Med. 2005, v. 171, р. 315-322.
- Borderias L., Mincewicz G., Parriaro P et al. Asthma control in patient with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study. Current Medical Respiratory Opinions. 2007, v. 23, р. 721-730.
- Braido F., Riccio A.M., Rogkakou A. et al. Montelukast effects on inflammation in allergic rhinitis: a double blind placebo controlled pilot study. Eur. Ann. Allergy Clin. Immunol. 2012, v 44, р. 48-53.
- Guibas G., Evangellia S., Makris M. et al. Montelucast exerts therapeutic action in a rat experimental model of allergic rhinitis/asthma. Abstr. CD of Europ. Academy of Allerg. and Clin. Immun. Congress (Geneva, Switzerland, 16-20 June 2012), No. 864.
Supplementary files
